Skip to content
OpenCapital
Get started

ImmunityBio, Inc. IBRX Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Merck & Co. logo
Merck & Co.MRK
$4.13B+35.0%
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s indefinite-lived research and development assets?
ImmunityBio, Inc. (IBRX) reported indefinite-lived research and development assets of $62K in Q1 2026.
How has ImmunityBio, Inc.'s indefinite-lived research and development assets changed year-over-year?
ImmunityBio, Inc.'s indefinite-lived research and development assets decreased by 87.8% year-over-year, from $510K to $62K.
What is the long-term trend for ImmunityBio, Inc.'s indefinite-lived research and development assets?
Over 3 years (2022 to 2025), ImmunityBio, Inc.'s indefinite-lived research and development assets has grown at a -66.6% compound annual growth rate (CAGR), from $1.39M to $52K.